Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topotecan Liposomes Injection (TLI)
Topotecan Liposomes · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2) |
| B | EXPERIMENTAL | Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2) |
| Name | Type | Description |
|---|---|---|
| Topotecan Liposomes Injection (TLI) | DRUG | TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2) |
Inclusion Criteria: 1. Age ≥ 18 years 2. Histologically or cytologically confirmed advanced solid tumor that has relapsed, is refractory to standard treatment, or for whom there is no standard therapy available. 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 4. Normal organ ...
Top 20 of 83 competitors